Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — Technical Presentation (August 2021)

11 slides from Marinus Pharmaceuticals's technical presentation, Aug 17, 2021

  1. Slide 1: Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex: The CALM Study

    NASDAQ: MRNS @MarinusPharma Topline Ganaxolone Phase 2 Open - Label Results in Tuberous Sclerosis Complex: The CALM Study August 17, 2021 1

  2. Slide 2: Safe Harbor Statement

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 2 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they ar e forward - looking statements reflecting the current beliefs and expectations of management m

  3. Slide 3: TSC Phase 2 Open-Label Clinical Trial Design

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I PART A PART B Baseline (4 Weeks) GNX Titration (4 Weeks) GNX Maintenance (8 Weeks) Open - Label Extension (OLE) (24 Weeks) * Available to patients that respond to GNX as defined per protocol 3 TSC - Phase 2 Open - Label Clinical Trial Design Basel

  4. Slide 4: Subject Disposition

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 4 Subject Disposition Screened (n=24) Screen Failure (n=0) Discontinued in baseline (n=1) Safety/ITT* (n=23) Completed Part A (n=17, 73.9%) Discontinued Part A (n=6, 26.1%) Reason for discontinuation: Adverse Event: n=4, 17.4% Lack of Efficacy: n=

  5. Slide 5: Subject Demographics & Baseline Clinical Characteristics

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 5 Subject Demographics & Baseline Clinical Characteristics Demographic Ganaxolone (n=23) Age, median 11.0 >17 years old, n (%) 8 (34.8) ≤17 years old, n (%) 15 (65.2) Gender, n (%) Male 14 (60.9) Female 9 (34.8) Characteristic Ganaxolone (n=23) Ba

  6. Slide 6: Percent Reduction in Seizure Frequency

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 6 Percent Reduction in TSC - associated Seizure Frequency -200 -100 -80 -60 -40 -20 0 20 40 60 80 100 P e r c e n t r e d u c t i o n i n T S C - a s s o c i a t e d s e i z u r e f r e q u e n c y =median 16.6% -20 0 20 40 60 80 100 Percent reduc

  7. Slide 7: Proportion of Subjects Achieving ≥50% Reduction in Seizure Frequency

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 7 Proportion of Subjects Achieving ≥ 50% Reduction in TSC - associated Seizure Frequency Intent to Treat (n=23) +Cannabidiol (n=12) +Everolimus (n=11) 0 5 10 15 20 25 30 35 40 45 50 36.4 25.0 30.4 P e r c e n t o f p a t i e n t s

  8. Slide 8: Change in Focal Seizure Frequency

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 8 Change in Focal Seizure Frequency ► Seizures associated with TSC are predominately focal seizures • Focal seizure types accounted for >80% of all TSC - associated seizures in the Phase 2 study Subjects with Focal Seizure Types (n=19) 0 10 20 30

  9. Slide 9: Safety

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 9 Safety ► Ganaxolone was generally well - tolerated with somnolence reported as the most common adverse event consistent with previous studies • Four patients (17.4%) discontinued due to adverse events Preferred Term Ganaxolone (n=23) Any TEAE, n

  10. Slide 10: Summary

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 10 Summary ► Study enrolled a highly refractory patient population on multiple AEDs including cannabidiol and everolimus ► Approximately 1/3 rd of patients had a robust reduction in TSC - associated seizures including those on concomitant cannabid

  11. Slide 11: Phase 3 TSC Clinical Trial Enhancements

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 11 Phase 3 TSC Clinical Trial Enhancements ► Adjustment to weekly titration schedule • Aimed to further improve tolerability in TSC patients ► Seizure classification • Ensure seizures are being accurately documented and reliably counted through on

Marinus Pharmaceuticals — Technical Presentation (August 2021) on 6ix